scholarly article | Q13442814 |
P356 | DOI | 10.1097/00002030-200309050-00008 |
P698 | PubMed publication ID | 12960822 |
P50 | author | Hans-Jürgen Stellbrink | Q47158312 |
Jan van Lunzen | Q47159113 | ||
P2093 | author name string | Hans-Jürgen Stellbrink | |
Kurt Hertogs | |||
Christian Eggers | |||
Hans-Jörg Stürenburg | |||
P433 | issue | 13 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | HIV encephalopathy | Q18967433 |
viral drug resistance | Q71228770 | ||
P304 | page(s) | 1897-1906 | |
P577 | publication date | 2003-09-01 | |
P1433 | published in | AIDS | Q4651863 |
P1476 | title | Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration | |
P478 | volume | 17 |
Q34387874 | Antibodies to myelin oligodendrocyte glycoprotein in HIV-1 associated neurocognitive disorder: a cross-sectional cohort study |
Q37066982 | Antiretroviral therapy and central nervous system HIV type 1 infection |
Q34298792 | Antiretroviral therapy in macrophages: implication for HIV eradication |
Q36344916 | Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection |
Q36798111 | Better Antiretroviral Central Nervous System Penetration is Not Associated with Reduced Chronic Pain in People Living with Human Immunodeficiency Virus |
Q31155550 | CNS infections in immunocompromised patients |
Q38060571 | CSF penetration by antiretroviral drugs |
Q34080236 | Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research |
Q42233102 | Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients |
Q24814874 | Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment |
Q82029827 | Cerebrospinal fluid markers in central nervous system HIV infection and AIDS dementia complex |
Q58598991 | Changes in resting-state functional brain activity are associated with waning cognitive functions in HIV-infected children |
Q37715012 | Chapter 12- Brain as an HIV sequestered site: Use of nanoparticles as a therapeutic option |
Q44367684 | Clinical features, diagnosis and treatment of HIV-induced neuropsychiatric disorders |
Q28475360 | Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia |
Q33843510 | Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells |
Q37787605 | Could differential virological characteristics account for ongoing viral replication and insidious damage of the brain during HIV 1 infection of the central nervous system? |
Q34950897 | Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course |
Q33786313 | Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals |
Q37015519 | Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers |
Q37176655 | Effects of antiretroviral therapy on cognitive impairment |
Q42264249 | Genetic shift of env V3 loop viral sequences in patients with HIV-associated neurocognitive disorder during antiretroviral therapy. |
Q41712400 | HIV 1-associated neurocognitive disorder: current epidemiology, pathogenesis, diagnosis and management |
Q36552753 | HIV pharmacology: barriers to the eradication of HIV from the CNS. |
Q39548875 | HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy |
Q30234305 | HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. |
Q46812278 | Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy |
Q45549650 | Immunodetection of a hepatitis C virus (HCV) antigen and Thl/Th2 cytokines in cerebrospinal fluid of meningitis patients |
Q33911855 | Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia |
Q37395149 | Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. |
Q82029838 | Neuropharmacology of HIV/AIDS |
Q36003825 | Neuroprotective strategies for HIV-1 associated dementia. |
Q38247035 | Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system |
Q37371300 | Second assessment of NeuroAIDS in Africa |
Q36957941 | Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals |
Q37362071 | Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration? |
Q36906028 | The meningeal lymphatic system: a route for HIV brain migration? |
Q42203691 | Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics |
Q48687135 | Using gene delivery to protect HIV-susceptible CNS cells: inhibiting HIV replication in microglia. |
Q37390163 | Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system |
Search more.